Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial looking at chemotherapy with or without bevacizumab for mucinous ovarian cancer (mEOC)
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is comparing 2 different chemotherapy combinations with or without bevacizumab (Avastin) for a rare type of ovarian cancer called mucinous epithelial ovarian cancer. This trial is supported by Cancer Research UK.
Doctors usually treat ovarian cancer with surgery and chemotherapy. But doctors think that standard chemotherapy drugs used for ovarian cancer are not necessarily the best for this particular type. Mucinous ovarian cancer has a number of similarities with mucinous cancer found in the
This trial will compare standard chemotherapy with a new combination of chemotherapy already used to treat mucinous cancers of the digestive system. Doctors also want to try a newer drug called bevacizumab that doctors use to treat other types of cancer. Bevacizumab is a type of biological therapy called a monoclonal antibody.
The aim of the trial is to find out
- Which treatment works better to control cancer growth
- More about the side effects
Who can enter
You can enter this trial if you
- Have newly diagnosed stage 2, 3 or 4 mucinous cancer of the ovary or fallopian tube or you have stage 1 cancer that has come back and you have not had chemotherapy
- Are well enough to take part (performance status 0, 1 or 2)
- Are willing to use reliable contraception if there is any chance that you could become pregnant
- Have satisfactory blood and urine test results
- Are at least 18 years old
You cannot enter this trial if
- You have non mucinous epithelial ovarian cancer
- You have primary peritoneal cancer
- You have had chemotherapy, radiotherapy or any experimental treatment for ovarian or rectal cancer in the past
- Your cancer has spread to your brain
- You have significant heart problems
- You have had a mini stroke (TIA), a stroke or bleed into the brain in the last 6 months
- You have ever had numbness or tingling in fingers or toes (
- You have a wound, ulcer or bone fracture that has not healed properly
- You have significant bleeding problems or take a drug to thin the blood called warfarin
- You take aspirin and cannot stop taking it (you should not stop taking medication without talking to your doctor)
- You take drugs called bisphosphonates
- You have any surgery planned while you are having treatment on this trial
- You have high blood pressure that is not controlled with medication
- You had a severe injury a month before starting bevacizumab treatment
- You have had any other type of cancer in the last 5 years apart from cervical carcinoma insitu or basal cell skin cancer that has been successfully treated, or womb (endometrial) cancer if it was grade 1 or 2 and stage 1A
- You are pregnant or breastfeeding
- You have any other medical condition that the trial doctors think could prevent you from taking part
332 patients will take part in this trial. It is a randomised trial. The people taking part will be put into 4 different groups by a computer. Neither you nor your doctor can decide which group you are in.
You have the drugs in this trial in 3 week cycles of treatment. Everyone taking part in the trial will have up to 6 cycles of treatment.
Groups 1 and 2 will have carboplatin, and paclitaxel as a drip into a vein once every 3 weeks. Groups 3 and 4 will have oxaliplatin as a drip into a vein once every 3 weeks. They will also take capecitabine as a tablet everyday for the first 2 weeks of each treatment cycle and then one week with no treatment.
If you are in groups 2 or 4, you will have bevacizumab as a drip into a vein on the same day as your other IV chemotherapy drugs. When your chemotherapy treatment finishes you will continue to have bevacizumab once every 3 weeks. You will have up to 12 cycles of treatment.
The researchers may ask your permission get a sample of the cancer tissue that was taken when you had surgery. They will study these samples to learn more about this type of cancer and how the treatment works. If you don’t want to give these samples, you don’t have to. You can still take part in the trial.
You will fill out a questionnaire when you join the trial, during treatment and at some of your follow up appointments. The questionnaires will ask about any side effects you have had and how you have been feeling. This is called a quality of life study.
You see the doctors and have some tests before you start treatment. The tests include
- Physical examination
- CT scan of your chest, stomach and lower abdomen (pelvic area)
- Blood tests
- Urine tests
You have your chemotherapy in the outpatient department. You have blood and urine tests before each treatment cycle begins.
You will have a CT scan or MRI scan after your third cycle of treatment and a month after your 6th cycle. After that, you have a scan at week 30, week 42, at the end of the first year, and then every 6 months in the next year and once a year for the following 3 years.
After you finish treatment, you go to the hospital to see the trial team every 6 weeks in the first year, every 3 months in the 2nd year and every 6 months for the next 3 years.
All treatments have side effects. The most common side effects of the chemotherapy drugs used in this trial are
- Feeling or being sick
- Sore mouth
- Loss of appetite
- Tiredness (fatigue)
- A drop in blood cells causing an increase risk of infection, bleeding problems, tiredness and breathlessness
The most common side effects of bevacizumab include
- High blood pressure during treatment
- Pain and weakness affecting your joints, muscles, chest and stomach
- Protein in your urine
- Increased risk of bleeding
- Slow wound healing
- Risk of blood clots
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Martin Gore
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
University College London (UCL)
This is Cancer Research UK trial number CRUK/08/008.